Geron Corporation
GERN Healthcare Biotechnology
Geron Corporation’s revenue for fiscal 2025 (year ended December 2025) was $183.9 million, up 138.8% from fiscal 2024. In the quarter to June 2026, revenue grew 17.2%, EPS was flat, free cash flow grew 41.8% and total debt was flat, each against the same quarter a year earlier.
Follow GERN
Geron Corporation (GERN) Piotroski F-score
Geron Corporation's Piotroski F-score for fiscal 2025 is 3 out of 9: 3 of nine tests of profitability, leverage and efficiency passed, unchanged from fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 3 | 0.00 |
| FY2024 | 3 | (1.00) |
| FY2023 | 4 | 2.00 |
| FY2022 | 2 | 0.00 |
| FY2021 | 2 | (1.00) |
| FY2020 | 3 | 2.00 |
| FY2019 | 1 | (3.00) |
| FY2018 | 4 | 2.00 |
| FY2017 | 2 | 0.00 |
| FY2016 | 2 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (14.34%) | (35.34%) | Fail | 0 |
| Positive operating cash flow | (111.04m) | (218.62m) | Fail | 0 |
| Rising return on assets | (14.34%) | (35.34%) | Pass | 1 |
| Cash flow above net income | (27.54m) | (44.05m) | Fail | 0 |
| Falling long-term leverage | 0.21 | 0.24 | Pass | 1 |
| Rising current ratio | 4.66 | 5.56 | Fail | 0 |
| No new shares issued | 666,663,000 | 646,033,300 | Fail | 0 |
| Rising gross margin | 97.42% | 98.37% | Fail | 0 |
| Rising asset turnover | 0.32 | 0.16 | Pass | 1 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 3 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| GERN Geron Corporation | 3 |
| DNA Ginkgo Bioworks Holdings, Inc. compare | 3 |
| ARDX Ardelyx, Inc. compare | 2 |
| SANA Sana Biotechnology, Inc. compare | — |
| VSTM Verastem, Inc. compare | — |
| HELP Cybin Inc. compare | — |
| CRVS Corvus Pharmaceuticals, Inc. compare | — |
| ALMS Alumis Inc. compare | — |
| AVBP ArriVent BioPharma, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover